NCT01738425View on ClinicalTrials.gov

A Clinical Phase I Study on GIC-1001 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Colonic Diseases
Interventions
DRUG

GIC-1001; 125 mg oral tablets

"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"

DRUG

GIC-1001 matching placebo

"Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]"

Trial Locations (1)

H7V 4B3

Algorithme Pharma Inc., Montreal

All Listed Sponsors
lead

gicare Pharma Inc.

INDUSTRY

NCT01738425 - A Clinical Phase I Study on GIC-1001 in Healthy Volunteers | Biotech Hunter | Biotech Hunter